The goal of this clinical trial is to study a personalized regime of lutetium-177 (177Lu) prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy (RPT) in patients with progressive and/or symptomatic, inoperable PSMA-expressing cancers of prostatic or other origins.
The main questions it aims to answer are:
* To establish a dosimetry-based, personalized regime of 177Lu-PSMA
* To report on the efficacy of personalized 177Lu-PSMA
Participants (stratified by risk factors of toxicity) will receive up to 6 cycles of a personalized activity of 177Lu-PSMA based on renal dosimetry. In the phase 1, the prescribed absorbed dose to the kidney will be escalated, to determine the regime that will be administered in the phase 2. The best response within 12 months after the first cycle will be assessed. Salvage treatment of 3 cycles may be offered to responders after re-progression.

Start Date01 Mar 2028

Sponsor / Collaborator

Centre Hospitalier Universitaire (CHU) de Québec-Université Laval

[+1]

CTIS2022-500570-33-00

/ RecruitingPhase 3

A Randomised, Open Label, Phase III, Multicenter, 2-arm study comparing 177Lu-PSMA-I&T versus Apalutamide/Enzalutamide/Abiraterone, in metastatic Hormon Sensitive Prostate Cancer Patients receiving castration treatment - Lut-AEA

Start Date20 Mar 2024

Sponsor / Collaborator

Region Västerbotten

IRCT20230803059015N1

/ SuspendedPhase 2IIT

Evaluating the theranostic application of Lu177-PSMA in management of refractory thyroid papillary cancer.

Start Date23 Aug 2023

Sponsor / Collaborator

Shiraz University of Medical Sciences

100 Clinical Results associated with 177Lu-PSMA-I&T

100 Translational Medicine associated with 177Lu-PSMA-I&T

100 Patents (Medical) associated with 177Lu-PSMA-I&T

Literatures (Medical) associated with 177Lu-PSMA-I&T

01 Apr 2025·Journal of Nuclear Medicine

Preclinical Evaluation of¹⁷⁷Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate Cancer: Biodistribution and Therapeutic Efficacy

Article

Author: Cornelissen, Bart ; Foxton, Caroline ; Waldron, Bradley ; Simón, Jaime Jim ; Stevens, Daniel ; Veggerby Grønlund, Rikke ; O'Neill, Edward

¹⁷⁷Lu-rhPSMA-10.1 is a novel radiohybrid prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy for prostate cancer. We conducted preclinical analyses on non-tumor-bearing BALB/c mice and on prostate cancer human xenograft mouse models (LNCAP and 22Rv1 xenografts) to evaluate its biodistribution and therapeutic efficacy. Methods: Longitudinal biodistribution of ¹⁷⁷Lu-rhPSMA-10.1 was evaluated in BALB/c mice and 22Rv1 xenografts. Tissues of interest were harvested, and radioactivity was measured 1-168 h after injection of 1 MBq of ¹⁷⁷Lu-rhPSMA-10.1 (4 per time point). Longitudinal biodistribution was compared with ¹⁷⁷Lu-PSMA-I&T (1 MBq) in BALB/c mice and at a single time point (15 h) in 22Rv1 xenografts. The therapeutic efficacy of a single administration of 15, 30, or 45 MBq of ¹⁷⁷Lu-rhPSMA-10.1 in LNCaP xenografts and 30 MBq of ¹⁷⁷Lu-rhPSMA-10.1, ¹⁷⁷Lu-PSMA-617, or ¹⁷⁷Lu-PSMA-I&T in 22Rv1 xenografts (8 per group) was evaluated. Efficacy versus vehicle was evaluated on the basis of relative tumor volume and survival up to 49 d after administration. Statistical significance was evaluated with t testing (biodistribution data), 2-way repeated-measures ANOVA (tumor volume [analyzed until 3 per group remained]), or Kaplan-Meier log-rank analyses (survival). Results: Biodistribution of ¹⁷⁷Lu-rhPSMA-10.1 in the BALB/c and 22Rv1 xenografts showed rapid clearance from blood and other normal tissues within 48 h, with the kidney showing the highest normal-organ uptake. Kidney uptake and retention were lower for ¹⁷⁷Lu-rhPSMA-10.1 than for ¹⁷⁷Lu-PSMA-I&T (6.5-fold lower at 12 h in BALB/c mice and 6.4-fold lower at 15 h in 22Rv1 xenografts; P < 0.01). High and sustained ¹⁷⁷Lu-rhPSMA-10.1 tumor uptake was observed in 22Rv1 xenografts. This uptake was 2.3-fold higher than that of ¹⁷⁷Lu-PSMA-I&T (15 h; P < 0.05). When efficacy was evaluated, ¹⁷⁷Lu-rhPSMA-10.1 significantly suppressed tumor growth versus vehicle from day 11 (P < 0.05) in LNCaP xenografts in a dose-dependent manner and from day 18 (P < 0.05) in 22Rv1 xenografts and significantly prolonged median survival versus vehicle in both models. In 22Rv1 xenografts, ¹⁷⁷Lu-rhPSMA-10.1 suppressed tumor growth versus vehicle to a greater extent than did ¹⁷⁷Lu-PSMA-I&T (significant growth inhibition from day 25 [P < 0.05]) and similarly in extent to ¹⁷⁷Lu-PSMA-617 (from day 18 [P < 0.05]). Overall, compared with ¹⁷⁷Lu-PSMA-I&T, ¹⁷⁷Lu-rhPSMA-10.1 suppressed tumor growth for longer than ¹⁷⁷Lu-PSMA-617 (inhibition from day 39 onward [P < 0.05] versus on day 49 only [P < 0.05]). Conclusion: In preclinical models, ¹⁷⁷Lu-rhPSMA-10.1 shows a favorable tumor-to-kidney uptake ratio, and significant antitumor effects, indicating it to be a promising next-generation radiopharmaceutical therapy.

01 Nov 2024·Annals of Nuclear Medicine

Comparative post-therapeutic dosimetry between 2D planar-based and hybrid-based methods for personalized Lu-177 treatment

Article

Author: Khamwan, Kitiwat ; Handayani, Wuri ; Chantadisai, Maythinee ; Phromphao, Benchamat ; Noipinit, Nut ; Pasawang, Panya

PURPOSEThis study aims to compare the calculated absorbed dose in target organs and tumors obtained using the different imaging protocols and the calculation methodologies implemented by HERMES HybridViewer dosimetry software for ¹⁷⁷Lu-PSMA I&T and ¹⁷⁷Lu-DOTATATE therapy.METHODSMultiple time-point whole-body planar images and one SPECT/CT image were acquired from 18 patients including ¹⁷⁷Lu-PSMA I&T (13 patients) and ¹⁷⁷Lu-DOTATATE treatment (5 patients) after administration of 3.80-8.58 GBq injected activity. The regions of interest were drawn in the whole body, kidneys, liver, urinary bladder, salivary glands, and tumors to determine the time-integrated activity (TIA) in source organs. Absorbed doses in target organs were calculated according to the Medical Internal Radiation Dose (MIRD) scheme using the HERMES HybridViewer dosimetry integrated with OLINDA/EXM V.2.1 that utilizes the non-uniform rational B-splines (NURBS) for computational digital phantom.RESULTSThe planar-based dosimetry showed a higher dose per injected activity compared to the hybrid-based dosimetry, primarily due to organ overlap. The highest difference in absorbed dose between the imaging scenarios was observed in the spleen with a variation of up to 51.6%, while the difference for other target organs and tumors was less than 40%.CONCLUSIONThe dosimetry calculation derived from the 2D planar-based method consistently demonstrates a significantly higher absorbed dose in organs and tumors compared with the hybrid-based method. However, the hybrid method outperforms the planar method in terms of tumor visualization and overlap-free organ delineation.

01 Oct 2024·Asia-Pacific Journal of Clinical Oncology

Outcomes and prognostic predictors of Lu‐177 PSMA radioligand therapy in metastatic castration‐resistant prostate cancer (Asian Population Study)

Article

Author: Lam, Winnie Wing‐Chuen ; Kua, Sandra Mei Yu ; Cheng, Tai Jit Lenith ; Ng, David Chee Eng ; Tong, Aaron Kian‐Ti ; Chua, Wei Ming ; Kanesvaran, Ravindran ; Wong, Alvin Seng Cheong ; Thang, Sue Ping ; Tay, Kae Jack ; Sultana, Rehena

AbstractAimLutetium‐177 (Lu‐177) prostate‐specific membrane antigen radioligand therapy (PSMA‐RLT) is a promising therapy for metastatic castration‐resistant prostate cancer (mCRPC), but there is limited data of its efficacy and safety in Asian population. We aim to explore the clinical outcomes of Lu‐177 PSMA‐RLT in this population.MethodsWe evaluated 84 patients with progressive mCRPC receiving Lu‐177 PSMA‐RLT between 9 May 2018 and 21 February 2022. Lu‐177‐PSMA‐I&T was administered at 6–8‐week intervals. Primary end point was overall survival (OS), and secondary end points included prostate‐specific antigen (PSA) progression‐free survival (PFS), PSA response rate, clinical response, toxicity assessment, and prognostic indicators.ResultsThe median OS and PSA PFS were 12.2 and 5.2 months, respectively. PSA decline of ≥50% was observed in 51.8% of patients. Patients achieving PSA response had longer median OS (15.0 vs. 9.5 months, p = .03) and PSA PFS (6.5 vs. 2.9 months, p < .001). Pain score improvement was seen in 19 out of 34 patients. A hematotoxicity of ≥grade 3 was observed in 13 out of 78 patients. Multivariable analyses showed that PSA velocity, alkaline phosphatase, hemoglobin (Hb), and the number of treatment cycles were independent prognostic indicators for OS. The retrospective design was the main limitation of the study.ConclusionsOur study demonstrated a similar safety and efficacy of Lu‐177 PSMA‐RLT in Asian mCRPC patients compared to the existing literature. A PSA decline ≥50% was associated with longer OS and PSA PFS. Several prognostic indicators for patient outcomes were also identified.

News (Medical) associated with 177Lu-PSMA-I&T

13 Nov 2024

·pipelinereview.com

Curium Announces ECLIPSE Trial Has Met Primary Endpoint, Demonstrating a Statistically Significant and Clinically Meaningful Benefit for Patients With PSMA-Positive Metastatic Castration Resistant Prostate Cancer

ST. LOUIS, MO, USA I November 13, 2024 I Curium, a world leader in nuclear medicine, announced today that its ECLIPSE trial met its primary endpoint. ECLIPSE is a pivotal Phase 3, multi-center, open-label, randomized clinical trial comparing the safety and efficacy of 177 Lu-PSMA-I&T (INN: lutetium ( 177 Lu) zadavotide guraxetan) versus hormone therapy in patients with metastatic castration-resistant prostate cancer. The ECLIPSE trial demonstrated a statistically significant and clinically meaningful improvement in the median radiographic progression-free survival (rPFS) of patients with prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer (mCRPC) after treatment with up to 6 doses of 200 mCi (7.4 GBq) of 177 Lu-PSMA-I&T in patients previously treated with an androgen receptor pathway inhibitor (ARPI) compared to a change in ARPI. Sakir Mutevelic, MD, Curium’s Chief Medical Officer said : “This is a significant accomplishment for Curium, demonstrating in the pivotal confirmatory ECLIPSE trial a statistically significant and clinically meaningful benefit of PSMA-targeted radioligand therapy with 177 Lu-PSMA-I&T for patients with mCRPC. ECLIPSE is the first Phase 3 trial investigating a 200 mCi (7.4 GBq) dose of 177 Lu-PSMA-I&T administered every six weeks for up to six doses, demonstrating clinical benefit, in mCRPC patients before receiving taxane-based chemotherapy. Curium will continue to work with the FDA as the clinical trial data matures, on a regulatory submission plan for this potentially important product for patients, their caregivers, and the healthcare providers treating prostate cancer.” Michael Patterson, CEO, Curium North America added: “The ECLIPSE achievement of its primary endpoint represents an important clinical milestone in the development of our prostate theranostic program. This underscores Curium’s continued commitment and focus on nuclear medicine diagnostics and therapeutics. Further, the announcement of the opening of Curium’s Netherlands facility for the production of 177 Lutetium in September 2024, bolsters Curium’s supply chain and ensures manufacturing reliability. Curium will continue to work to fulfill its mission of redefining the experience of cancer through our trusted legacy in nuclear medicine by ensuring unrestricted access to this important product, if approved.” About Curium Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service. With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit www.curiumpharma.com . SOURCE: Curium

Phase 3Clinical Result

03 Oct 2024

·www.globenewswire.com

Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan

Collaboration to include the clinical development, regulatory filing, and commercialization in Japan of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T Builds on long-standing relationship between the two companies In Japan around 90,000 new cases of prostate cancer are diagnosed each year Oct. 01, 2024 -- Curium, a world leader in nuclear medicine, announced today that it has entered into a strategic partnership with PDRadiopharma Inc, a wholly-owned subsidiary of PeptiDream, for the clinical development, regulatory filing, and commercialization in Japan of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T. The two agents 177Lu-PSMA-I&T and 64Cu-PSMA-I&T target prostate specific membrane antigen (PSMA) expressed on prostate cancer cells and are being investigated for prostate cancer treatment and diagnostics. Both target tumors with high levels of PSMA expression and thus potentially forming a theranostic (therapeutic & diagnostic) pair. Under the terms of the partnership, Curium and PDRadiopharma will jointly collaborate on clinical development activities of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T in Japan, with PDRadiopharma leading regulatory filing, manufacturing, commercialization, and distribution activities in Japan. Curium will continue to lead global development of the two agents and support PDRadiopharma through technology transfer to support the set-up of manufacturing lines in Japan – including a high throughput Copper 64 manufacturing line based on Curium’s proprietary technology. Patrick C. Reid, President & CEO of PeptiDream commented: “Targeted radiopharmaceuticals are rapidly revolutionizing how we both diagnose and treat cancer. At PeptiDream and PDRadiopharma we are focused on expanding our pipeline of these powerful targeted therapies, and we are thrilled to be able to accelerate those efforts by partnering with Curium to bring their highly promising prostate cancer targeting radiopharmaceuticals to patients in Japan.” Masato Murakami, President of PDRadiopharma & CMO of PeptiDream commented: “We are excited to partner with Curium in the development of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T, highly promising products for both the diagnosis and treatment of PSMA-expressing prostate cancer. We look forward to working with Curium to deliver these much-needed agents to prostate cancer patients in Japan as quickly as possible.” Chaitanya Tatineni, Curium’s CEO International Markets commented: “As a global innovator in the field of radiopharmaceuticals with a promising late-stage oncology pipeline, Curium is delighted to partner with PDRadiopharma which has more than four decades of experience in Japan. Curium and PDRadiopharma plan to leverage their complementary strengths to accelerate the development of innovative products for the benefit of prostate cancer patients in Japan.” Prostate cancer continues to be widely prevalent in Japan. Annually, there are approximately 90,000 – 100,000 new cases, with patients with metastatic castration-resistant prostate cancer having an overall survival rate of approximately three years in clinical trial settings, and even shorter in the real-world, and there remains a significant unmet medical need for therapies. 177Lu-PSMA-I&T, a PSMA inhibitor conjugated with the radioisotope Lutetium 177, is currently being tested by Curium in a global pivotal Phase 3 ECLIPSE trial (ClinicalTrials.gov identifier; NCT05204927). ECLIPSE is a multi-center, open-label, randomized clinical trial comparing the safety and efficacy of 177Lu-PSMA-I&T versus hormone therapy in patients with metastatic castration-resistant prostate cancer. The ECLIPSE trial enrolled over 400 patients, across 51 trial sites in the United States and Europe. 64Cu-PSMA-I&T PET is currently being investigated in 2 multicenter Phase 3 trials; SOLAR RECUR testing the diagnostic performance in men with biochemical recurrence of prostate cancer (ClinicalTrials.gov identifier NCT06235099) and SOLAR STAGE testing the diagnostic performance in men with newly diagnosed unfavorable intermediate- to high-risk prostate cancer (ClinicalTrials.gov identifier; NCT06235151). The first in human Phase 1/2 SOLAR trial met the co-primary endpoints of region-level correct localization rate and patient-level correct detection rate in patients with histologically-proven metastatic prostate cancer. PSMA-targeted PET/CT imaging is increasingly emerging as a highly sensitive method for detection of locally recurrent or metastatic lesions in the context of biochemical recurrence and for localization of primary prostate cancer. Curium and PDRadiopharma have a long-standing relationship in the radiopharmaceutical field. PeptiDream Inc. (Tokyo Stock Exchange Prime Market 4587) is leading the translation of macrocyclic peptides into a whole new class of innovative medicines to address unmet medical needs and improve the quality of life of patients worldwide. In its radiopharmaceutical business, through its wholly-owned subsidiary PDRadiopharma, PeptiDream markets and sells a number of approved radiopharmaceuticals and radiodiagnostics in Japan, as well as leveraging its proprietary Peptide Discovery Platform System (PDPS) technology to discover and develop a deep pipeline of innovative targeted radiotherapeutics and radiodiagnostics, spanning both wholly-owned internal programs and globally partnered programs. In its non-radiopharmaceutical business, PeptiDream is similarly leveraging PDPS to discover and develop a broad and diverse pipeline of investigational peptide therapeutics, peptide drug conjugates (PDC) and multi-functional peptide conjugates (MPC) across an extensive global network of discovery and development partners. PeptiDream is headquartered in Kawasaki, Japan. For more information about our company, science and pipeline, please visit www.peptidream.com/en PDRadiopharma, a wholly-owned subsidiary of PeptiDream since 2022, has been providing high-quality radiopharmaceuticals through the research and development, manufacturing, regulatory and sales as a forerunner in the field in radiopharmaceuticals, since it started its business in 1968. PDRadiopharma currently markets 21 radiodiagnostic products (spanning both SPECT and PET products) and 8 radiotherapeutic products (3 product categories) in Japan. Additionally, PDRadiopharma and PeptiDream are developing a broad pipeline of radiotherapeutics and radiodiagnostics for both the Japan and global markets. For more information about PDRadiopharma, please visit www.pdradiopharma.com/en Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service. With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit www.curiumpharma.com The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultLicense out/in

12 May 2022

·www.biospace.com

Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial

ST. LOUIS, May 12, 2022 (GLOBE NEWSWIRE) -- Curium confirmed today no supply challenges of 177Lu-PSMA-I&T for the Phase 3 ECLIPSE clinical trial (NCT05204927), evaluating Lutetium 177Lu-PSMA-I&T treatment compared to the standard of care hormone therapy in men with metastatic Castration-Resistant Prostate Cancer (mCRPC). Curium continues to provide clinical trial supply, and enroll patients in the ECLIPSE clinical trial with no disruptions. “Earlier this month we announced significant progress in our ECLIPSE clinical trial. We are enrolling eligible patients into our study of 177Lu-PSMA-I&T without disruption, which is a testament to our surety of supply. Reliability is a core competency for Curium and is fundamental to fulfilling our purpose of redefining the experience of cancer through our trusted legacy in nuclear medicine,” said Renaud Dehareng, Curium’s Group CEO. “We are thrilled to be able to reliably support our patients, investigators and clinical trial sites,” said Sakir Mutevelic, MD, Curium’s Chief Medical Officer. “We remain committed to patients with metastatic castration-resistant prostate cancer.” For more information about the ECLIPSE Trial, visit Curium’s Clinical Trial website https://www.curiumpharma.com/clinical-trials/ or contact Curium’s Clinical Trial team directly at ECLIPSE@curiumpharma.com with questions or to locate a clinical trial site near you. About Curium Curium is the world’s largest nuclear medicine company. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence and unparalleled service. With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit curiumpharma.com.

Radiation Therapy

100 Deals associated with 177Lu-PSMA-I&T

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastasis from malignant tumor of prostate	Phase 3	Spain	Curium US Holdings LLC	14 Feb 2022
Metastasis from malignant tumor of prostate	Phase 3	France	Curium US Holdings LLC	14 Feb 2022
Metastasis from malignant tumor of prostate	Phase 3	United States	Curium US Holdings LLC	14 Feb 2022
Metastasis from malignant tumor of prostate	Phase 3	Italy	Curium US Holdings LLC	14 Feb 2022
Metastatic castration-resistant prostate cancer	Phase 3	France	Curium US Holdings LLC	14 Feb 2022
Metastatic castration-resistant prostate cancer	Phase 3	Italy	Curium US Holdings LLC	14 Feb 2022
Metastatic castration-resistant prostate cancer	Phase 3	Spain	Curium US Holdings LLC	14 Feb 2022
Metastatic castration-resistant prostate cancer	Phase 3	United States	Curium US Holdings LLC	14 Feb 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05204927 (PipelineReview) Manual	Phase 3	Metastatic castration-resistant prostate cancer	-	177Lu-PSMA-I&T	(mbjpyaxjwq) = atqbfrtvfa nmatzqvwdj (yxwfjzpcww )	Positive	13 Nov 2024
				Hormone therapy	(mbjpyaxjwq) = uzskhqkhur nmatzqvwdj (yxwfjzpcww )
SNMMI2024	Not Applicable	-	-	[177Lu]Lu-PSMA I&T	smfodychjg(lkyjevyrku) = No CTC grade ≥III occurred after RLT eejebojzkn (jolalmgjfj ) View more	-	09 Jun 2024
SNMMI2024	Not Applicable	Prostatic Cancer	-	177Lu-PSMA-617	uuytjzpkkr(juzwllkvde) = cdhrbnrzhi iuijosuwbt (mbfiajxvmb ) View more	-	09 Jun 2024
				177Lu-PSMA-I&T	uuytjzpkkr(juzwllkvde) = zdiqbytmol iuijosuwbt (mbfiajxvmb ) View more
EANM2022	Not Applicable	PSMA-Positive Tumor PSMA	8	Ac-225-PSMA-I&T	tzlnpbwoqd(sfeubxjttu) = grgicxkjqi jdcpncxaju (xqsmrosrnm, 58.7)	-	22 Sep 2022
				Lu-177-PSMA-I&T	tzlnpbwoqd(sfeubxjttu) = dgrpguotqw jdcpncxaju (xqsmrosrnm, 12.0)
SNMMI2022	Not Applicable	Prostatic Cancer	-	177Lu-PSMA-617	vtxmapwmvz(hyenwqhmlb) = txvcqqlglo fdzcipgdcm (tnwcefnooi, 8) View more	-	08 Aug 2022
				177Lu-PSMA-I&T	vtxmapwmvz(hyenwqhmlb) = pfsszzkrsm fdzcipgdcm (tnwcefnooi, 5) View more
NCT04188587 (Pubmed \| Front Oncol) Manual	Phase 2	Metastatic castration-resistant prostate cancer	40	177 Lu-PSMA-I&T	(ogpijtzinc) = rsklawggtu mmsgydxjgd (ltguaeobxt ) View more	Positive	24 Mar 2022
AUA2021	Not Applicable	Prostatic Cancer PSMA avidity	7	177Lu-PSMA-I&T	(luntilhncu) = The only reported adverse event during LuPSMA treatment was fatigue in 1 patient (14%) xeipshctjz (pmuggocbgb ) View more	-	01 Sep 2021
EANM2018	Not Applicable	Prostatic Cancer	6	177 Lu-PSMA I&T (SPECT/CT imaging)	gojltvxdwl(zptcqefpcg) = jttwpqrqvm umpxpjwelp (gkpxltkwku )	-	18 Sep 2018
				177 Lu-PSMA I&T (Planar imaging)	gojltvxdwl(zptcqefpcg) = dzzytqjhnm umpxpjwelp (gkpxltkwku )
EANM2016	Not Applicable	Metastatic Prostate Carcinoma PSMA	-	Lu-177 PSMA I&T	dlayxybigb(zqtkiverzi) = cnlrmkzxkg bwqsdrlmyw (syqarogkmo ) View more	-	21 Sep 2016
				Lu-177 PSMA-617	dlayxybigb(zqtkiverzi) = qlqtvlliel bwqsdrlmyw (syqarogkmo ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis